Radiochemotherapy in the elderly with lung cancer

Casas, Francesc; Kępka, Lucyna; Agarwal, Jai Prakash; Dawotola, D.; Gaye, Papa Macoumba; Abdelwahab, Sherif; Vashkevitch, L.; Saghatelyan, Tatul; Perin, B; Jeremić, Branislav

doi:10.1586/era.09.110

Cited by 11 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-small cell lung cancer (NSCLC) is the most common type which represents more than 80% of lung cancer [3]. Lung cancer is the leading cause of cancer mortality throughout the world, including Koreas [4]. …”

Section: Introductionmentioning

confidence: 99%

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer

Kang

Jeong

et al. 2012

Radiat Oncol J

View full text Add to dashboard Cite

PurposeCombined chemoradiotherapy is standard management for locally advanced non-small cell lung cancer (LA-NSCLC), but standard treatment for elderly patients with LA-NSCLC has not been confirmed yet. We evaluated the feasibility and efficacy of concurrent chemoradiotherapy (CCRT) for elderly patients with LA-NSCLC.Materials and MethodsAmong patients older than 65 years with LA-NSCLC, 36 patients, who underwent CCRT were retrospectively analyzed. Chemotherapy was administered 3-5 times with 4 weeks interval during radiotherapy. Thoracic radiotherapy was delivered to the primary mass and regional lymph nodes. Total dose of 54-59.4 Gy (median, 59.4 Gy) in daily 1.8 Gy fractions and 5 fractions per week.ResultsRegarding the response to treatment, complete response, partial response, and no response were shown in 16.7%, 66.7%, and 13.9%, respectively. The 1- and 2-year overall survival (OS) rates were 58.2% and 31.2%, respectively, and the median survival was 15 months. The 1- and 2-year progression-free survivals (PFS) were 41.2% and 19.5%, respectively, and the median PFS was 10 months. Regarding to the toxicity developed after CCRT, pneumonitis and esophagitis with grade 3 or higher were observed in 13.9% (5 patients) and 11.1% (4 patients), respectively. Treatment-related death was not observed.ConclusionThe treatment-related toxicity as esophagitis and pneumonitis were noticeably lower when was compared with the previously reported results, and the survival rate was higher than radiotherapy alone. The results indicate that CCRT is an effective in terms of survival and treatment related toxicity for elderly patients over 65 years old with LA-NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer

Kang

Jeong

et al. 2012

Radiat Oncol J

View full text Add to dashboard Cite

show abstract

“…3,4 Elderly patients who participated in Phase III trials for stage III NSCLC were likely to gain a survival advantage from RT and chemotherapy (CT) compared with RT alone, although, as in the case of younger patients, there was an additional toxicity with this therapy modality. 5…”

Section: Introductionmentioning

confidence: 99%

Treatment of lung cancer in the elderly: Influence of comorbidity on toxicity and survival

Cardia

Calçada

Pereira

2011

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Three-dimensional conformal radiotherapy with doses up to 70 Gy is less effective than surgery and many patients experience local recurrence [18, 19]. …”

Section: Discussionmentioning

confidence: 99%

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity

Türzer

Brustugun²,

Waldeland

et al. 2011

Case Rep Oncol

View full text Add to dashboard Cite

Background: The purpose of this study was to assess stereotactic body radiation therapy (SBRT) results and toxicity for stage I non-small cell lung cancer patients with low performance status and severe comorbidity. Patients and Methods: From September 2008 to April 2010, 36 patients with 38 lesions were treated with hypofractionated SBRT. All except one were medically inoperable, had low performance status and/or severe cardiovascular and/or cardiopulmonary comorbidity. The patients were immobilized in an Elekta stereotactic body frame to improve setup accuracy, and four-dimensional CT scans were used for target delineation. Fractions of 15 Gy were prescribed to cover the planning target volume, giving a total dose of 45 Gy, with 1 fraction every second day. Cone beam CT was applied at each fraction to correct for setup errors. The patients were followed with toxicity evaluation and radiographic follow-up. Results: Median follow-up time was 13.8 months (0–21 months). The local tumor control after 12 months was 100%. Four patients developed regional relapse about 12 months after SBRT. The 1-year disease-free survival was 83%. The median tumor shrinkage at 1 year was 22 mm. Three patients experienced systemic relapse after 13 months. One patient developed grade 3 chest pain toxicity and 16 patients reported temporary grade 1 chest pain toxicity. Two patients reported temporary increased dyspnea. No patient experienced a reduction of the performance status after SBRT. Conclusion: SBRT is an effective and safe treatment modality for elderly patients with early-stage non-small cell lung cancer, having low performance status and severe comorbidity. It is possible to achieve high local control rates with good tolerance.

show abstract

Radiochemotherapy in the elderly with lung cancer

Cited by 11 publications

References 43 publications

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer

Treatment of lung cancer in the elderly: Influence of comorbidity on toxicity and survival

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity

Contact Info

Product

Resources

About